---
title: "Neuphoria Therapeutics to receive $15M milestone payment from Merck"
date: "2025-02-12 15:25:30"
summary: "Neuphoria Therapeutics (NASDAQ:NEUP) is due to receive a $15 million milestone payment from Merck, the company said on Wednesday. The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Neuphoria Therapeutics (NASDAQ:[NEUP](https://seekingalpha.com/symbol/NEUP "Neuphoria Therapeutics Inc.")) is due to receive a $15 million milestone payment from Merck, the company said on Wednesday.
* The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator ([PAM](https://seekingalpha.com/symbol/PAM "Pampa Energía S.A.")), for the treatment of the symptoms of Alzheimer’s disease dementia.
* Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain development and commercial milestones associated with the progress of multiple candidates plus royalties on net sales of any licensed medicines.
* Source: [Press Release](https://seekingalpha.com/pr/19999514-neuphoria-therapeutics-inc-to-receive-15m-milestone-payment-from-merck)

[seekalpha](https://seekingalpha.com/news/4406746-neuphoria-therapeutics-to-receive-15m-milestone-payment-from-merck)
